Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES (CardiacAging)
Diastolic Dysfunction, Systolic Dysfunction, Diastolic Heart Failure
About this trial
This is an interventional treatment trial for Diastolic Dysfunction focused on measuring Sulforaphane, oxidative stress, HFpEF, HFrEF, Arterial function, Muscle function
Eligibility Criteria
Inclusion Criteria:
- Age > 60 years
- Diagnosis of HFpEF (HF symptoms with a normal EF (>/=50 %)
- Ability to walk more than 500 feet (by self-report)
- Willing to avoid taking all over the counter antioxidant phytochemical supplements (vegetable or fruit-containing supplement pills) during the study
Exclusion Criteria:
- Inability to provide informed consent
- Diagnosis of active cancer
- Inability to read and understand the SF-36 in English
- Participants using over the counter antioxidant supplements
- Participants with pulmonary or other issues which restrict walking capacity
- On oxygen therapy
Sites / Locations
- Texas Tech University Health Sciences Center (TTUHSC)Recruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Avmacol ES
Placebo
Processed SFN-rich extract will be purchased from Nutramax Laboratories, Inc. 2208 Lakeside Blvd Edgewood, MD 21040. Caplets containing SFN-rich broccoli sprout extracts will be obtained from Nutramax Labs. Study medication will be dispensed in sealed bottles with instructions to keep them in a household freezer. The size of the caplet will be about the size of a 1000 mg Vit C pill (about 2 cm in length). The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets. Participants will be instructed to take a daily dose for 24 weeks based on the participants weight. Two caplets for individuals <100 lb., three caplets for individuals 100-200 lb. and four caplets for individuals >200 lb. SFN (Avmacol Extra Strength) will be prescribed by a study physician, and will be dispensed by the study coordinators at TTUHSC Lubbock. Pill counts will be conducted to demonstrate compliance.
Placebo caplets containing microcrystalline cellulose will be obtained from Nutramax Labs. Study medication will be dispensed in sealed bottles with instructions to keep them in a household freezer. The size of the caplet will be about the size of a 1000 mg Vit C pill (about 2 cm in length). The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets. Participants will be instructed to take a daily dose for 24 weeks based on the participants weight. Two caplets for individuals <100 lb., three caplets for individuals 100-200 lb. and four caplets for individuals >200 lb. Placebo will be prescribed by a study physician, and will be dispensed by the study coordinators at TTUHSC Lubbock. Pill counts will be conducted to demonstrate compliance.